JP2015533176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533176A5 JP2015533176A5 JP2015537018A JP2015537018A JP2015533176A5 JP 2015533176 A5 JP2015533176 A5 JP 2015533176A5 JP 2015537018 A JP2015537018 A JP 2015537018A JP 2015537018 A JP2015537018 A JP 2015537018A JP 2015533176 A5 JP2015533176 A5 JP 2015533176A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ezh2
- pharmaceutically acceptable
- compound according
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261714145P | 2012-10-15 | 2012-10-15 | |
| US201261714140P | 2012-10-15 | 2012-10-15 | |
| US61/714,140 | 2012-10-15 | ||
| US61/714,145 | 2012-10-15 | ||
| US201361780703P | 2013-03-13 | 2013-03-13 | |
| US61/780,703 | 2013-03-13 | ||
| US201361786277P | 2013-03-14 | 2013-03-14 | |
| US61/786,277 | 2013-03-14 | ||
| PCT/US2013/065126 WO2014062732A1 (en) | 2012-10-15 | 2013-10-15 | Substituted benzene compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018028891A Division JP2018087238A (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533176A JP2015533176A (ja) | 2015-11-19 |
| JP2015533176A5 true JP2015533176A5 (enExample) | 2016-12-01 |
| JP6461802B2 JP6461802B2 (ja) | 2019-01-30 |
Family
ID=50475881
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537019A Expired - Fee Related JP6461803B2 (ja) | 2012-10-15 | 2013-10-15 | 置換ベンゼン化合物 |
| JP2015537018A Expired - Fee Related JP6461802B2 (ja) | 2012-10-15 | 2013-10-15 | 置換ベンゼン化合物 |
| JP2018028891A Withdrawn JP2018087238A (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
| JP2018028907A Expired - Fee Related JP6559275B2 (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537019A Expired - Fee Related JP6461803B2 (ja) | 2012-10-15 | 2013-10-15 | 置換ベンゼン化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018028891A Withdrawn JP2018087238A (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
| JP2018028907A Expired - Fee Related JP6559275B2 (ja) | 2012-10-15 | 2018-02-21 | 置換ベンゼン化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US10092572B2 (enExample) |
| EP (4) | EP3628662A1 (enExample) |
| JP (4) | JP6461803B2 (enExample) |
| KR (2) | KR102057365B1 (enExample) |
| CN (3) | CN105102432B (enExample) |
| AR (1) | AR093244A1 (enExample) |
| AU (2) | AU2013331381B2 (enExample) |
| BR (2) | BR112015008480A2 (enExample) |
| CA (2) | CA2887562C (enExample) |
| CL (2) | CL2015000942A1 (enExample) |
| HK (2) | HK1213552A1 (enExample) |
| IL (4) | IL238135B (enExample) |
| MX (2) | MX2015004721A (enExample) |
| MY (1) | MY180311A (enExample) |
| NZ (2) | NZ706738A (enExample) |
| PE (2) | PE20150886A1 (enExample) |
| PH (2) | PH12015500800B1 (enExample) |
| RU (2) | RU2658919C2 (enExample) |
| SG (3) | SG10201705989YA (enExample) |
| TW (2) | TWI651303B (enExample) |
| UA (2) | UA119136C2 (enExample) |
| WO (2) | WO2014062733A2 (enExample) |
| ZA (2) | ZA201502526B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN105102432B (zh) | 2012-10-15 | 2019-01-04 | Epizyme股份有限公司 | 经取代的苯化合物 |
| KR102021642B1 (ko) | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| JP2016503009A (ja) | 2012-12-13 | 2016-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | Ｚｅｓｔｅホモログ２エンハンサー阻害剤 |
| CA2894216A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| AU2013361079B2 (en) * | 2012-12-21 | 2018-07-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| EP2970271B1 (en) | 2013-03-14 | 2017-11-08 | Janssen Pharmaceutica NV | P2x7 modulators |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
| AU2014230814B2 (en) | 2013-03-14 | 2017-12-21 | Boehringer Ingelheim International Gmbh | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3019494B1 (en) | 2013-07-10 | 2017-06-21 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3057962B1 (en) | 2013-10-16 | 2023-10-18 | Epizyme, Inc. | Hydrochloride salt form for ezh2 inhibition |
| EP3076977B1 (en) | 2013-12-06 | 2021-03-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| BR112016029492A2 (pt) | 2014-06-17 | 2017-10-17 | Eisai R&D Man Co Ltd | método para tratamento de linfoma não hodgkin |
| WO2016039977A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
| UA118610C2 (uk) | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
| JP6625616B2 (ja) | 2014-09-12 | 2019-12-25 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７調節ｎ−アシル−トリアゾロピラジン |
| MX383635B (es) * | 2014-10-16 | 2025-03-14 | Epizyme Inc | Método para tratar el cáncer. |
| SG11201703806XA (en) | 2014-11-17 | 2017-06-29 | Epizyme Inc | Method for treating cancer |
| EP3236962A2 (en) | 2014-12-23 | 2017-11-01 | University of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| EA201792304A1 (ru) | 2015-04-20 | 2018-03-30 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| AU2016275051A1 (en) | 2015-06-10 | 2017-12-07 | Epizyme, Inc. | EZH2 inhibitors for treating lymphoma |
| CN108025191A (zh) | 2015-08-24 | 2018-05-11 | Epizyme股份有限公司 | 治疗癌症的方法 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| WO2017132518A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3445365A4 (en) * | 2016-04-22 | 2019-10-16 | Dana-Farber Cancer Institute, Inc. | EZH2 INHIBITORS AND USES THEREOF |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| CN108699002B (zh) * | 2016-11-11 | 2021-11-09 | 上海海雁医药科技有限公司 | 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2018223030A1 (en) | 2017-06-02 | 2018-12-06 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| NZ766447A (en) | 2018-01-31 | 2021-12-24 | Mirati Therapeutics Inc | Prc2 inhibitors |
| JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのｐｒｃ２サブユニットの阻害 |
| TW202035409A (zh) | 2018-09-28 | 2020-10-01 | 比利時商健生藥品公司 | 單醯基甘油脂肪酶調節劑 |
| MY205440A (en) | 2018-09-28 | 2024-10-21 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| AU2020288563A1 (en) | 2019-06-05 | 2022-01-06 | Mirati Therapeutics, Inc. | Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| AU2020358948A1 (en) | 2019-09-30 | 2022-05-26 | Janssen Pharmaceutica Nv | Radiolabelled MGL PET ligands |
| CN111303133A (zh) * | 2020-03-25 | 2020-06-19 | 清华大学 | 降解ezh2蛋白的小分子化合物 |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| CA3230149A1 (en) * | 2021-08-30 | 2023-03-09 | Xiaojing Zhang | Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma |
| CN116655612A (zh) * | 2023-05-09 | 2023-08-29 | 王亚男 | 一种ezh2抑制剂的合成方法及应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| NZ277556A (en) | 1993-12-27 | 1997-06-24 | Eisai Co Ltd | N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| WO2000018725A1 (en) | 1998-09-30 | 2000-04-06 | The Procter & Gamble Company | 2-substituted ketoamides |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| KR100828982B1 (ko) | 2000-12-28 | 2008-05-14 | 시오노기세이야쿠가부시키가이샤 | 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체 |
| EP1363702A4 (en) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
| EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| AU2003292556B2 (en) | 2002-12-27 | 2009-09-10 | Sucampo Ag | Derivatives of prostaglandins for treating abdominal discomfort |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| EP1633740B1 (en) | 2003-06-19 | 2011-11-09 | GlaxoSmithKline LLC | 5-(acylamino)indazole derivatives as kinase inhibitors |
| DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| EP1663194B1 (en) | 2003-08-26 | 2010-03-31 | Merck HDAC Research, LLC | Use of SAHA for treating mesothelioma |
| US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| AU2005229522A1 (en) | 2004-03-11 | 2005-10-13 | Actelion Pharmaceuticals Ltd. | Indol-1-yl-acetic acid derivatives |
| CN1286973C (zh) | 2004-04-12 | 2006-11-29 | 上海第二医科大学附属瑞金医院 | 一种组蛋白甲基转移酶及其制备方法 |
| DE602005017781D1 (de) | 2004-06-01 | 2009-12-31 | Univ North Carolina | Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7923219B2 (en) | 2005-06-02 | 2011-04-12 | The University Of North Carolina At Chapel Hill | Ubiquitin E3 ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| KR101347102B1 (ko) | 2005-10-19 | 2014-01-03 | 그뤼넨탈 게엠베하 | 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도 |
| EP1951672B1 (en) | 2005-10-21 | 2011-05-25 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| WO2007053480A2 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
| EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2007087015A1 (en) | 2006-01-20 | 2007-08-02 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| MX2008014616A (es) | 2006-05-15 | 2008-11-28 | Irm Llc | Compuestos y composiciones de tereftalamato, y su uso como inhibidores de integrasa de vih. |
| EP2040711A2 (en) | 2006-05-18 | 2009-04-01 | Amphora Discovery Corporation | 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents |
| EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | NEUROPROTEKTIVE COMPOSITIONS AND METHOD |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2008109534A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| CA2690619A1 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| AU2008337286B2 (en) | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| US8558000B2 (en) | 2008-01-23 | 2013-10-15 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| AU2009279616A1 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| UY32275A (es) | 2009-03-24 | 2010-06-30 | Sanofi Aventis | DERIVADOS DE AZACARBOLINAS 9H-PIRROLO[2,3-b:5,4-c'] DIPIRIDINA, SU PREPARACION Y SU UTILIZACIÓN TERAPÉUTICA. |
| EP2411007A4 (en) | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| WO2011082044A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| US8536179B2 (en) | 2010-05-07 | 2013-09-17 | Glaxosmithkline Llc | Indoles |
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US8765792B2 (en) | 2010-12-01 | 2014-07-01 | Glaxosmithkline Llc | Indoles |
| AU2011336272A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| US8791782B2 (en) * | 2011-01-28 | 2014-07-29 | Uses, Inc. | AC power conditioning circuit |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| HUE042271T2 (hu) * | 2012-03-12 | 2019-06-28 | Epizyme Inc | Emberi EZH2 inhibitorai és azok alkalmazási eljárásai |
| KR102117982B1 (ko) | 2012-04-13 | 2020-06-03 | 에피자임, 인코포레이티드 | 암 치료용 병용 요법 |
| DK3628670T3 (da) | 2012-04-13 | 2022-12-05 | Epizyme Inc | Saltform til ezh2-hæmning |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| KR102021642B1 (ko) * | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| CN105102432B (zh) * | 2012-10-15 | 2019-01-04 | Epizyme股份有限公司 | 经取代的苯化合物 |
-
2013
- 2013-10-15 CN CN201380065683.2A patent/CN105102432B/zh active Active
- 2013-10-15 EP EP19188699.3A patent/EP3628662A1/en not_active Withdrawn
- 2013-10-15 KR KR1020157012670A patent/KR102057365B1/ko not_active Expired - Fee Related
- 2013-10-15 RU RU2015118145A patent/RU2658919C2/ru active
- 2013-10-15 SG SG10201705989YA patent/SG10201705989YA/en unknown
- 2013-10-15 US US14/435,704 patent/US10092572B2/en active Active
- 2013-10-15 CN CN201380065677.7A patent/CN105102431B/zh active Active
- 2013-10-15 MY MYPI2015000966A patent/MY180311A/en unknown
- 2013-10-15 JP JP2015537019A patent/JP6461803B2/ja not_active Expired - Fee Related
- 2013-10-15 US US14/054,695 patent/US9006242B2/en active Active
- 2013-10-15 BR BR112015008480A patent/BR112015008480A2/pt not_active IP Right Cessation
- 2013-10-15 KR KR1020157012673A patent/KR102057366B1/ko not_active Expired - Fee Related
- 2013-10-15 HK HK16101447.9A patent/HK1213552A1/zh unknown
- 2013-10-15 MX MX2015004721A patent/MX2015004721A/es active IP Right Grant
- 2013-10-15 JP JP2015537018A patent/JP6461802B2/ja not_active Expired - Fee Related
- 2013-10-15 MX MX2015004722A patent/MX353929B/es active IP Right Grant
- 2013-10-15 UA UAA201504699A patent/UA119136C2/uk unknown
- 2013-10-15 RU RU2015118135A patent/RU2662436C2/ru active
- 2013-10-15 CA CA2887562A patent/CA2887562C/en active Active
- 2013-10-15 TW TW106111749A patent/TWI651303B/zh not_active IP Right Cessation
- 2013-10-15 EP EP13847763.3A patent/EP2906538A4/en not_active Withdrawn
- 2013-10-15 AU AU2013331381A patent/AU2013331381B2/en not_active Ceased
- 2013-10-15 WO PCT/US2013/065127 patent/WO2014062733A2/en not_active Ceased
- 2013-10-15 CN CN201811510752.7A patent/CN110041250A/zh active Pending
- 2013-10-15 SG SG11201502803VA patent/SG11201502803VA/en unknown
- 2013-10-15 AU AU2013331380A patent/AU2013331380B2/en not_active Ceased
- 2013-10-15 PE PE2015000488A patent/PE20150886A1/es active IP Right Grant
- 2013-10-15 UA UAA201504700A patent/UA115074C2/uk unknown
- 2013-10-15 CA CA2888021A patent/CA2888021A1/en not_active Abandoned
- 2013-10-15 AR ARP130103745A patent/AR093244A1/es active IP Right Grant
- 2013-10-15 SG SG11201502820YA patent/SG11201502820YA/en unknown
- 2013-10-15 BR BR112015008487-7A patent/BR112015008487B1/pt not_active IP Right Cessation
- 2013-10-15 TW TW102137117A patent/TWI588131B/zh not_active IP Right Cessation
- 2013-10-15 EP EP13846696.6A patent/EP2906537B1/en active Active
- 2013-10-15 WO PCT/US2013/065126 patent/WO2014062732A1/en not_active Ceased
- 2013-10-15 PE PE2015000489A patent/PE20150887A1/es active IP Right Grant
- 2013-10-15 NZ NZ706738A patent/NZ706738A/en not_active IP Right Cessation
- 2013-10-15 HK HK16101355.9A patent/HK1213264A1/zh unknown
- 2013-10-15 EP EP20161557.2A patent/EP3725314A1/en not_active Withdrawn
- 2013-10-15 NZ NZ706739A patent/NZ706739A/en not_active IP Right Cessation
-
2015
- 2015-03-05 US US14/639,878 patent/US9089575B2/en active Active
- 2015-04-02 IL IL238135A patent/IL238135B/en active IP Right Grant
- 2015-04-10 PH PH12015500800A patent/PH12015500800B1/en unknown
- 2015-04-12 IL IL238197A patent/IL238197A0/en active IP Right Grant
- 2015-04-15 PH PH12015500825A patent/PH12015500825A1/en unknown
- 2015-04-15 CL CL2015000942A patent/CL2015000942A1/es unknown
- 2015-04-15 CL CL2015000944A patent/CL2015000944A1/es unknown
- 2015-04-15 ZA ZA2015/02526A patent/ZA201502526B/en unknown
- 2015-04-16 ZA ZA2015/02560A patent/ZA201502560B/en unknown
- 2015-06-17 US US14/742,466 patent/US9532992B2/en active Active
-
2016
- 2016-11-22 US US15/359,538 patent/US10098888B2/en active Active
-
2018
- 2018-02-21 JP JP2018028891A patent/JP2018087238A/ja not_active Withdrawn
- 2018-02-21 JP JP2018028907A patent/JP6559275B2/ja not_active Expired - Fee Related
- 2018-09-04 US US16/120,702 patent/US20190060322A1/en not_active Abandoned
- 2018-09-26 IL IL261964A patent/IL261964B/en active IP Right Grant
-
2019
- 2019-03-18 IL IL265437A patent/IL265437A/en unknown
-
2020
- 2020-07-09 US US16/924,962 patent/US11642348B2/en active Active
-
2023
- 2023-03-23 US US18/188,700 patent/US20240165121A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015118135A (ru) | Содержащие заместители бензольные соединения | |
| JP2017008088A5 (enExample) | ||
| JP2009514880A5 (enExample) | ||
| JP2009514881A5 (enExample) | ||
| JP2018535951A5 (enExample) | ||
| JP2020514311A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
| JP2016515561A5 (enExample) | ||
| JP2017517520A5 (enExample) | ||
| JP2012153722A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2015533177A5 (enExample) | ||
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| JP2018517686A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2018524347A5 (enExample) | ||
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| NZ706999A (en) | Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof | |
| JP2019506392A5 (enExample) | ||
| JP2018536636A5 (enExample) | ||
| JP2017528475A5 (enExample) | ||
| JP2018522045A5 (enExample) | ||
| JP2018525358A5 (enExample) | ||
| JP2016525097A5 (enExample) |